Bindery

Bindery is a biotechnology company dedicated to the development of programmable protein medicines through de novo protein design. Founded by pioneers in the field of computational biology, the company utilizes a proprietary platform to engineer small, stable, and highly potent protein binders that can target biological pathways with extreme precision. These synthetic proteins are designed to address the limitations of traditional monoclonal antibodies, offering potential advantages in tissue penetration, stability, and manufacturing. Bindery is currently operating in the pre-clinical stage, focusing its initial efforts on high-impact targets within oncology and inflammatory diseases. The company is backed by leading life science investors, including ARCH Venture Partners and GV.